Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9123.1140
Address
Level 17 350 Queen Street Melbourne, Victoria (VIC) 3000
Description
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.18
Trade Value (12mth)
AU$18,178.00
1 week
0%
1 month
0%
YTD
-40.86%
1 year
-6.47%
All time high
15.95
EPS 3 yr Growth
-2.60%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-37.50%
ROIC
-32.90%
Interest Coverage
-113.90
Quick Ratio
2.00
Shares on Issue (Fully Dilluted)
204m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 April 25 |
ACCENT Data Update Presented at International Conference
×
ACCENT Data Update Presented at International Conference |
09 April 25 |
US Clinical Trial Activities for Narmafotinib Now Underway
×
US Clinical Trial Activities for Narmafotinib Now Underway |
27 March 25 |
Encouraging Updated Data from Pancreatic Cancer Trial
×
Encouraging Updated Data from Pancreatic Cancer Trial |
03 March 25 |
Type D Meeting Outcome With US Food And Drug Administration
×
Type D Meeting Outcome With US Food And Drug Administration |
13 February 25 |
Listing Rule 3.11.2 - change of Exercise Price of Options
×
Listing Rule 3.11.2 - change of Exercise Price of Options |
31 January 25 |
Completion of Recruitment of ACCENT Trial
×
Completion of Recruitment of ACCENT Trial |
30 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
20 January 25 |
New Narmafotinib Data Presented at International Conference
×
New Narmafotinib Data Presented at International Conference |
10 January 25 |
Release of Shares from Voluntary Escrow
×
Release of Shares from Voluntary Escrow |
23 December 24 |
Security Class Reinstatement to Quotation - ATXOA
×
Security Class Reinstatement to Quotation - ATXOA |
20 December 24 |
Notification regarding unquoted securities - ATX
×
Notification regarding unquoted securities - ATX |
20 December 24 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
20 December 24 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
20 December 24 |
Top 20 Holders and Range of Units for Attaching Options
×
Top 20 Holders and Range of Units for Attaching Options |
20 December 24 |
Change of Director's Interest Notice - Ms Jane Bell
×
Change of Director's Interest Notice - Ms Jane Bell |
20 December 24 |
Change of Director's Interest Notice - Dr Robert Peach
×
Change of Director's Interest Notice - Dr Robert Peach |
20 December 24 |
Change of Director's Interest Notice - Dr Chris Burns
×
Change of Director's Interest Notice - Dr Chris Burns |
20 December 24 |
Change of Director's Interest Notice - Dr Warwick Tong
×
Change of Director's Interest Notice - Dr Warwick Tong |
20 December 24 |
Section 708A(5)(e) Notice - Allotment of 2,826,087 Shares
×
Section 708A(5)(e) Notice - Allotment of 2,826,087 Shares |
19 December 24 |
Results of Meeting - EGM 19 Dec 2024
×
Results of Meeting - EGM 19 Dec 2024 |
11 December 24 |
Positive Data Strong Recruitment in Pancreatic Cancer Trial
×
Positive Data Strong Recruitment in Pancreatic Cancer Trial |
28 November 24 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
27 November 24 |
Successful Completion of Retail Entitlement Offer
×
Successful Completion of Retail Entitlement Offer |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.